Steven Hoerter Net Worth & Insider Trades
Steven Hoerter - President and CEO, Deciphera Pharmaceuticals, Inc
What is Steven Hoerter's Net Worth?
The current estimated net worth of Deciphera Pharmaceuticals, Inc's President and CEO, Steven Hoerter, is estimated to be about $9.53M . Steven Hoerter owns about 0 unit of Deciphera Pharmaceuticals, Inc common stock. In the last 5 years at Deciphera Pharmaceuticals, Inc, Steven Hoerter has sold an estimated value of $1.23M worth.
What is Steven Hoerter's Past Insider Trading?
Steven Hoerter's largest sale order was 30,045 units , worth over $480.72K on February 16, 2023. In total, Steven Hoerter has made about 17 transactions over 5 years of their time at Deciphera Pharmaceuticals, Inc. Steven Hoerter usually trades in March, with the busiest year in 2020. The most recent transaction was a sale order of 7,500 units , worth over $116.78K on March 23, 2023.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Steven Hoerter
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
InsideArbitrage
What was Steven Hoerter's Salary in 2020?
As President and CEO of Deciphera Pharmaceuticals, Inc, Steven Hoerter has a total base salary of $650,000 . Steven Hoerter received compensation valued at about $7,794,944 in 2020 after becoming President and CEO. The vast majority of their compensation came in the form of option awards of $6,597,306 , other earnings, plans or compensations of $536,250 , and other compensation of $11,388 .
What is Steven Hoerter's' Mailing Address?
- Mailing address is 2525 28th Street, Suite 100 Boulder CO 80301 CO
Deciphera Pharmaceuticals, Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|---|
| Steven L. Hoerter | 2020 | $650,000 | - | - | $6,597,306 | $536,250 | $11,388 | $7,794,944 |
| Steven L. Hoerter | 2019 | $449,886 | - | $1,320,800 | $6,776,000 | $478,500 | - | $9,025,186 |
| Thomas P. Kelly | 2020 | $447,200 | - | $386,285 | $1,546,335 | $272,278 | $7,386 | $2,659,484 |
| Thomas P. Kelly | 2019 | $430,000 | - | - | $1,308,788 | $336,690 | $11,200 | $2,086,678 |
| Thomas P. Kelly | 2018 | $370,000 | - | - | $1,755,252 | $175,000 | $11,000 | $2,311,252 |
| Matthew L. Sherman, M.D. | 2020 | $504,986 | - | $96,571 | $385,576 | $307,461 | $5,962 | $1,300,556 |
| Matthew L. Sherman, M.D. | 2019 | $125,000 | $150,000 | $1,205,050 | $3,458,715 | $84,593 | $115,164 | $5,138,522 |
| Daniel L. Flynn, Ph.D. | 2020 | $442,000 | - | $386,285 | $1,546,335 | $269,112 | $11,400 | $2,655,132 |
| Daniel C. Martin | 2020 | $436,800 | - | $386,285 | $1,546,335 | $247,141 | $23,882 | $2,640,443 |
| Daniel C. Martin | 2019 | $420,000 | - | - | $907,426 | $253,344 | $505,549 | $2,086,319 |
| Daniel C. Martin | 2018 | $117,875 | $100,000 | $722,000 | $2,189,097 | $45,000 | $702 | $3,174,674 |
| Stephen B. Ruddy, Ph.D. | 2020 | $383,400 | - | $386,285 | $1,546,335 | $216,928 | $1,212 | $2,534,160 |
| No matching records found | ||||||||
Source: https://www.sec.gov/Archives/edgar/data/1654151/000165415121000007/dcph-2021xproxystatement.htm
What are Deciphera Pharmaceuticals, Inc's Past Insider Trades?
Deciphera Pharmaceuticals, Inc's most recent insider trade came on October 4, 2023 by Matthew Sherman who sold 2,942 units worth $37.3K . In the last 6 years, insiders at Deciphera Pharmaceuticals, Inc have sold an estimated value of $103.51M and bought an estimated value of $63.62M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Douglas Michael Taylor, Director, Patrick Thomas Kelly, Chief Financial Officer, and Lee Daniel Flynn, Chief Scientific Officer .
Deciphera Pharmaceuticals, Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||